Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor β (TGFβ) receptor II leading to cancer cell death

Sanjib Chowdhury, Gillian M. Howell, Carol A. Teggart, Aparajita Chowdhury, Jonathan J. Person, Dawn M. Bowers, Michael G. Brattain

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Survivin is a cancer-associated gene that functions to promote cell survival, cell division, and angiogenesis and is a marker of poor prognosis. Histone deacetylase inhibitors induce apoptosis and re-expression of epigenetically silenced tumor suppressor genes in cancer cells. In association with increased expression of the tumor suppressor gene transforming growth factor β receptor II (TGFβRII) induced by the histone deacetylase inhibitor belinostat, we observed repressed survivin expression. We investigated the molecular mechanisms involved in survivin down-regulation by belinostat downstream of reactivation of TGFβ signaling. We identified two mechanisms. At early time points, survivin protein half-life was decreased with its proteasomal degradation. We observed that belinostat activated protein kinase A at early time points in a TGFβ signaling-dependent mechanism. After longer times (48 h), survivin mRNA was also decreased by belinostat. We made the novel observation that belinostat mediated cell death through the TGFβ/protein kinase A signaling pathway. Induction of TGFβRII with concomitant survivin repression may represent a significant mechanism in the anticancer effects of this drug. Therefore, patient populations exhibiting high survivin expression with epigenetically silenced TGFβRII might potentially benefit from the use of this histone deacetylase inhibitor.

Original languageEnglish (US)
Pages (from-to)30937-30948
Number of pages12
JournalJournal of Biological Chemistry
Volume286
Issue number35
DOIs
StatePublished - Sep 2 2011

Fingerprint

Histone Deacetylase Inhibitors
Growth Factor Receptors
Transforming Growth Factors
Cell death
Cell Death
Neoplasms
Genes
Cells
Cyclic AMP-Dependent Protein Kinases
Tumor Suppressor Genes
Tumors
Neoplasm Genes
Cell Division
Half-Life
belinostat
Cell Survival
Down-Regulation
Observation
Association reactions
Apoptosis

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor β (TGFβ) receptor II leading to cancer cell death. / Chowdhury, Sanjib; Howell, Gillian M.; Teggart, Carol A.; Chowdhury, Aparajita; Person, Jonathan J.; Bowers, Dawn M.; Brattain, Michael G.

In: Journal of Biological Chemistry, Vol. 286, No. 35, 02.09.2011, p. 30937-30948.

Research output: Contribution to journalArticle

Chowdhury, Sanjib ; Howell, Gillian M. ; Teggart, Carol A. ; Chowdhury, Aparajita ; Person, Jonathan J. ; Bowers, Dawn M. ; Brattain, Michael G. / Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor β (TGFβ) receptor II leading to cancer cell death. In: Journal of Biological Chemistry. 2011 ; Vol. 286, No. 35. pp. 30937-30948.
@article{fe648b7a75174b6b8b1d2e936142b7c6,
title = "Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor β (TGFβ) receptor II leading to cancer cell death",
abstract = "Survivin is a cancer-associated gene that functions to promote cell survival, cell division, and angiogenesis and is a marker of poor prognosis. Histone deacetylase inhibitors induce apoptosis and re-expression of epigenetically silenced tumor suppressor genes in cancer cells. In association with increased expression of the tumor suppressor gene transforming growth factor β receptor II (TGFβRII) induced by the histone deacetylase inhibitor belinostat, we observed repressed survivin expression. We investigated the molecular mechanisms involved in survivin down-regulation by belinostat downstream of reactivation of TGFβ signaling. We identified two mechanisms. At early time points, survivin protein half-life was decreased with its proteasomal degradation. We observed that belinostat activated protein kinase A at early time points in a TGFβ signaling-dependent mechanism. After longer times (48 h), survivin mRNA was also decreased by belinostat. We made the novel observation that belinostat mediated cell death through the TGFβ/protein kinase A signaling pathway. Induction of TGFβRII with concomitant survivin repression may represent a significant mechanism in the anticancer effects of this drug. Therefore, patient populations exhibiting high survivin expression with epigenetically silenced TGFβRII might potentially benefit from the use of this histone deacetylase inhibitor.",
author = "Sanjib Chowdhury and Howell, {Gillian M.} and Teggart, {Carol A.} and Aparajita Chowdhury and Person, {Jonathan J.} and Bowers, {Dawn M.} and Brattain, {Michael G.}",
year = "2011",
month = "9",
day = "2",
doi = "10.1074/jbc.M110.212035",
language = "English (US)",
volume = "286",
pages = "30937--30948",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "35",

}

TY - JOUR

T1 - Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor β (TGFβ) receptor II leading to cancer cell death

AU - Chowdhury, Sanjib

AU - Howell, Gillian M.

AU - Teggart, Carol A.

AU - Chowdhury, Aparajita

AU - Person, Jonathan J.

AU - Bowers, Dawn M.

AU - Brattain, Michael G.

PY - 2011/9/2

Y1 - 2011/9/2

N2 - Survivin is a cancer-associated gene that functions to promote cell survival, cell division, and angiogenesis and is a marker of poor prognosis. Histone deacetylase inhibitors induce apoptosis and re-expression of epigenetically silenced tumor suppressor genes in cancer cells. In association with increased expression of the tumor suppressor gene transforming growth factor β receptor II (TGFβRII) induced by the histone deacetylase inhibitor belinostat, we observed repressed survivin expression. We investigated the molecular mechanisms involved in survivin down-regulation by belinostat downstream of reactivation of TGFβ signaling. We identified two mechanisms. At early time points, survivin protein half-life was decreased with its proteasomal degradation. We observed that belinostat activated protein kinase A at early time points in a TGFβ signaling-dependent mechanism. After longer times (48 h), survivin mRNA was also decreased by belinostat. We made the novel observation that belinostat mediated cell death through the TGFβ/protein kinase A signaling pathway. Induction of TGFβRII with concomitant survivin repression may represent a significant mechanism in the anticancer effects of this drug. Therefore, patient populations exhibiting high survivin expression with epigenetically silenced TGFβRII might potentially benefit from the use of this histone deacetylase inhibitor.

AB - Survivin is a cancer-associated gene that functions to promote cell survival, cell division, and angiogenesis and is a marker of poor prognosis. Histone deacetylase inhibitors induce apoptosis and re-expression of epigenetically silenced tumor suppressor genes in cancer cells. In association with increased expression of the tumor suppressor gene transforming growth factor β receptor II (TGFβRII) induced by the histone deacetylase inhibitor belinostat, we observed repressed survivin expression. We investigated the molecular mechanisms involved in survivin down-regulation by belinostat downstream of reactivation of TGFβ signaling. We identified two mechanisms. At early time points, survivin protein half-life was decreased with its proteasomal degradation. We observed that belinostat activated protein kinase A at early time points in a TGFβ signaling-dependent mechanism. After longer times (48 h), survivin mRNA was also decreased by belinostat. We made the novel observation that belinostat mediated cell death through the TGFβ/protein kinase A signaling pathway. Induction of TGFβRII with concomitant survivin repression may represent a significant mechanism in the anticancer effects of this drug. Therefore, patient populations exhibiting high survivin expression with epigenetically silenced TGFβRII might potentially benefit from the use of this histone deacetylase inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=80052255348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052255348&partnerID=8YFLogxK

U2 - 10.1074/jbc.M110.212035

DO - 10.1074/jbc.M110.212035

M3 - Article

C2 - 21757750

AN - SCOPUS:80052255348

VL - 286

SP - 30937

EP - 30948

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 35

ER -